Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2

Interventions

pembrolizumab 1273Specimen Handling 871Carboplatin 832Magnetic Resonance Spectroscopy 808Cyclophosphamide 803Cisplatin 729Nivolumab 659Paclitaxel 631Radiotherapy 574Gemcitabine 572Biopsy 529Bevacizumab 476Dexamethasone 440fludarabine 407Docetaxel 378venetoclax 370Oxaliplatin 365Capecitabine 358Fluorouracil 355atezolizumab 344durvalumab 334Rituximab 333Doxorubicin 317Radiosurgery 309Pemetrexed 306Drug Therapy 303Ipilimumab 294Standard of Care 293Etoposide 285Radiation 281

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × ibritumomab tiuxetan × 1 year × Clear all
NCT00690560 2026-05-22

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Centre Antoine Lacassagne

Phase 2 Completed
30 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT01359592 2025-06-17

S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

SWOG Cancer Research Network

Phase 2 Completed
159 enrolled 21 charts
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡